Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Apr 5;3(1):23-35.
doi: 10.15586/jkcvhl.2016.46. eCollection 2016.

Sequential Therapy in Metastatic Renal Cell Carcinoma

Bradford R Hirsch  1 , John M Burke  1 , Manish Agrawal  1 , Ralph J Hauke  1 , Thomas E Hutson  1 , Gury Doshi  1 , Mark T Fleming  1 , Nicholas J Vogelzang  1
Affiliations
Review

Sequential Therapy in Metastatic Renal Cell Carcinoma

Bradford R Hirsch et al. J Kidney Cancer VHL. .

Abstract

The treatment of metastatic renal cell carcinoma (mRCC) has changed dramatically in the past decade. As the number of available agents, and related volume of research, has grown, it is increasingly complex to know how to optimally treat patients. The authors are practicing medical oncologists at the US Oncology Network, the largest community-based network of oncology providers in the country, and represent the leadership of the Network's Genitourinary Research Committee. We outline our thought process in approaching sequential therapy of mRCC and the use of real-world data to inform our approach. We also highlight the evolving literature that will impact practicing oncologists in the near future.

Keywords: kidney cancer; renal cell carcinoma; sequential therapy.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: Hirsch: research funding—Pfizer, Bristol Meyers Squibb, Dendron, GlaxoSmithKline, Astellas, Sanofi; advisory board—Astellas, Pfizer, Hospira, Sandoz, Genentech; and stock/ownership interest—SignalPath Research, Flatiron Health. Hutson: research, speaker, advisory board/consultant: Pfizer, Novartis, Bayer, BMS, Eisai, Aveo. Burke: advisory boards—Gilead, Incyte, Millennium, Janssen Pfizer; travel—TG Therapeutics. Vogelzang: research funding from Pfizer, Novartis, Bayer, BMS, and Exelixis. Hauke, Doshi, Fleming, and Agrawal declare no potential conflict of interest with respect to research, authorship and/or publication of this article.

Figures

Figure 1.
Figure 1.
Treatment decision tree for first- and second-line therapy in metastatic renal cell carcinoma based on available and evolving evidence. Bev: bevacizumab; HFS: hand foot syndrome; IFNα: interferon alfa; PFS: progression free survival.
See this image and copyright information in PMC

References

    1. Centerwatch. Approved drugs by therapeutic area [Internet]. 2015. [cited 2015 June 22]. Available from: http://www.centerwatch.com/drug-information/fda-approvals/drug-areas.asp....
    1. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–13. http://dx.doi.org/10.1056/NEJMoa1510665. - DOI - PMC - PubMed
    1. Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, et al. METEOR Investigators. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1814–23. http://dx.doi.org/10.1056/NEJMoa1510016. - DOI - PMC - PubMed
    1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Kidney Cancer. Washington, PA: NCCN; 2014.
    1. European Association of Urology. Guidelins in Renal Cell Carcinoma. Arnheim, Netherlands: EAU; 2015.

LinkOut - more resources